Salud financiera de hoja de balance de Observe Medical

Salud financiera controles de criterios 4/6

Observe Medical tiene un patrimonio de los accionistas total de NOK107.4M y una deuda total de NOK56.0M, lo que sitúa su ratio deuda-patrimonio en 52.1%. Sus activos y pasivos totales son NOK246.4M y NOK139.0M respectivamente.

Información clave

52.1%

Ratio deuda-patrimonio

NOK 55.97m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	NOK 2.70m
Patrimonio	NOK 107.45m
Total pasivo	NOK 138.95m
Activos totales	NOK 246.40m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Jun 27

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Sep 23

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Jun 07

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Feb 08

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

Sep 11

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Mar 02

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (NOK28.3M) de OBSRV no cubren sus pasivos a corto plazo (NOK111.8M).

Pasivo a largo plazo: Los activos a corto plazo de OBSRV (NOK28.3M) superan a sus pasivos a largo plazo (NOK27.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de OBSRV (49.6%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de OBSRV ha pasado de 161.6% a 52.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: OBSRV tiene suficiente cash runway para 2 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que OBSRV disponga de suficiente cash runway para 1 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Observe Medical

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Recent updates

New major risk - Share price stability

First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023)

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical Asa Announces CFO Changes

Full year 2023 earnings released: kr1.05 loss per share (vs kr1.08 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Chief Financial Officer exercised options to buy kr149k worth of stock.

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

New major risk - Share price stability

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Third quarter 2022 earnings released: kr0.28 loss per share (vs kr0.43 loss in 3Q 2021)

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Observe Medical ASA Announces Executive Appointments

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Full year 2021 earnings released: kr1.34 loss per share (vs kr2.22 loss in FY 2020)

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: kr29.80

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: kr16.00

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: kr14.70

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: kr11.40

New 90-day low: kr11.90

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: kr12.00

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: kr13.20

Earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera